Verge Genomics Announces the Addition of Mario Saltarelli, M.D., Ph.D., to its Scientific Advisory Board

SAN FRANCISCO--(BUSINESS WIRE)--Verge Genomics, a drug discovery company developing therapies for neurological diseases by integrating a unique all-in-human genomic platform with machine learning, announced today that Mario Saltarelli, M.D., Ph.D., CEO of U.S. Green Valley Pharmaceuticals, has been appointed to Verge’s Scientific Advisory Board. Dr. Saltarelli is a neurologist, drug...

Click to view original post